Kite Pharma has received FDA priority review for its axicabtagene ciloleucel biologics license application.

The submission follows positive data demonstrated with a single infusion of axicabtagene ciloleucel in a Phase II clinical trial in patients with refractory aggressive non-Hodgkin lymphoma.

The FDA has set a target action date of Nov. 29.